Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Ascendiant Capital analyst Edward Woo has maintained a 'Buy' rating on Atossa Therapeutics (NASDAQ: ATOS) and raised the price target from $24 to $25. This adjustment reflects a positive outlook for the company's stock performance.